StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 0.6 %
Shares of TTNP opened at $7.20 on Friday. Titan Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $16.90. The firm’s 50 day moving average price is $7.20 and its 200 day moving average price is $7.30.
Hedge Funds Weigh In On Titan Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in TTNP. Virtu Financial LLC acquired a new position in shares of Titan Pharmaceuticals during the second quarter worth $35,000. Millennium Management LLC boosted its position in shares of Titan Pharmaceuticals by 516.8% during the 2nd quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 52,874 shares in the last quarter. State Street Corp purchased a new position in shares of Titan Pharmaceuticals in the 3rd quarter valued at about $41,000. Finally, Renaissance Technologies LLC raised its position in shares of Titan Pharmaceuticals by 559.3% during the 2nd quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company’s stock worth $135,000 after acquiring an additional 204,200 shares in the last quarter. 31.49% of the stock is owned by institutional investors and hedge funds.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- 4 Golden Crosses With Double-Digit Upside Ahead
- Health Care Stocks Explained: Why You Might Want to Invest
- All-Aboard! Greenbrier Companies Breaks Out, New Highs Ahead
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 High Dividend Socks to Replace Lower Savings Yields Ahead
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
